Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Price inflation driven by old and new drugs

Hernandez I et al. Health Aff (Millwood). 2019 Jan. doi: 10.1377/hlthaff.2018.05147

Publish date:: January 24, 2019

Key clinical point: Price inflation in existing drugs and new product introductions are driving increases in pharmaceutical costs.

Major finding: 71% of oral specialty drug price increases during 2005-2019 are attributable to new products.

Study details: Researchers analyzed the wholesale acquisition prices of 24,877 oral drugs and 3,049 injectable drugs and compared them with pharmacy claims across all public and private insurance products offered by the UPMC Health Plan.

Disclosures: The authors provided no disclosures.

Read the article here.

Citation:

Hernandez I et al. Health Aff (Millwood). 2019 Jan. doi: 10.1377/hlthaff.2018.05147.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Practice Management

Family planning issues loom large for female radiation oncologists,

Men occupy most leadership roles in medicine,

Video coaching may relieve anxiety and distress for long-distance cancer caregivers,

COVID-19 death rate was twice as high in cancer patients in NYC study,

More doctors used digital tools in 2019,